
Conference Coverage
Latest Content

Pertuzumab Biosimilar Gains FDA Approval for HER2+ Breast Cancer

Daraxonrasib Gains EC Approval in Previously Treated Metastatic Pancreatic Cancer

Cretostimogene Grenadenorepvec Improves RFS in Intermediate-Risk and High-Grade Ta NMIBC

FDA Approves Giredestrant Plus Everolimus for ER+/HER2–, ESR1-Mutated Metastatic Breast Cancer

The Pan-Mass Challenge Exceeds 2026 Fundraising Goal with Record-Breaking $80 Million Gift Fueling Lifesaving Research at Dana-Farber Cancer Institute

OncLive TV
Shorts










Continuing Medical Education
All News

Onvansertib plus FOLFIRI/bevacizumab earned fast track status in first-line KRAS- or NRAS-mutated metastatic colorectal cancer.

The FDA cited the lack of a significant OS benefit in HARMONi for ivonescimab plus chemotherapy after EGFR TKI therapy in NSCLC.

An interim phase 1/2 trial update found that DB107-RRV plus DB107-FC could be given in combination with radiation in newly diagnosed high-grade glioma.

Many patients with IDH-mutant glioma continued to receive vorasidenib as directed in the real-world GLIO-ADHERE claims analysis.

Mirdametinib produced stable disease or partial responses in adults and children with plexiform neurofibromas who had received another MEK inhibitor.

Longer follow-up of the phase 3 INDIGO trial showed that vorasidenib lowered seizure rates in IDH-mutant glioma, an effect driven by oligodendroglioma.

The top 5 OncLive TV videos of the week cover insights in HER2+ breast cancer, NSCLC, ovarian cancer, prostate cancer, and sarcoma.

Many patients with BRAF-altered pediatric low-grade glioma stayed off therapy after planned tovorafenib cessation in the 4-year FIREFLY-1 update.

The FDA approved pimicotinib for tenosynovial giant cell tumor, accepted a gedatolisib filing in advanced breast cancer, and more.

Serial amino acid PET flagged responses earlier than MRI in IDH-mutant glioma treated with vorasidenib, interim data show.

Longer mirdametinib treatment increased confirmed and deep responses as treatment-related adverse effects declined in neurofibromatosis type 1 tumors.

Patrick Forde, MD, MBBCh, details how chemoimmunotherapy, pathologic response, and targeted therapy are reshaping resectable NSCLC care.

Long-term data show that plixorafenib yielded durable responses and no cumulative adverse effects in BRAF-altered primary central nervous system tumors.

The FDA approved durvalumab plus enfortumab vedotin for cisplatin-ineligible muscle-invasive bladder cancer.

UCSF experts will present key research at the 31st Society for Neuro-Oncology Annual Meeting.

The filing is supported by phase 3 REZILIENT3 data showing a median PFS of 14.5 vs 8.5 months with zipalertinib plus chemotherapy vs chemotherapy.

A European Commission decision on belzutifan plus lenvatinib in pretreated advanced ccRCC is expected within 2 months, based on LITESPARK-011 data.

The phase 3 4WARD trial is evaluating mavorixafor for reducing infection rates and raising neutrophil counts in patients with primary chronic neutropenia.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Age, geographic location, transportation barriers, and language and communication barriers may limit patient opportunities to participate in research.

Targeting two alternate pathways at the same time led to improved outcomes in multiple preclinical models of advanced breast cancer.

Updated LEGEND cohort 1 data showed a 56% CR rate and a 24% 12-month CR rate with detalimogene in BCG-unresponsive, high-risk NMIBC with CIS.

Phase 2 Co-PSMA data showed higher lesion detection with 64Cu-SAR-bisPSMA vs 68Ga-PSMA-11 in biochemical recurrence after prostatectomy.

Mary Ann Anderson, MBBS, FRACP, FRCPA, PhD, discusses CLL17 trial data, resistance mechanisms, and emerging BTK degraders and bispecifics in CLL.

Check out this October recap of OncLive’s coverage of the top news and expert insights in gastrointestinal cancers.

Thomas Powles, MBBS, MRCP, MD, discusses LITESPARK-022 QOL findings and patient selection for adjuvant belzutifan plus pembrolizumab in RCC.

Gov. Hochul unveils a cell and gene therapy fellowship between Roswell Park and San Juan City Hospital to train Puerto Rico physicians in advanced cancer care.

Retrospective data tie longer survival with niraparib maintenance to homologous recombination deficiency after complete primary debulking.

A meta-analysis of 4 sonrotoclax cohorts showed consistent response activity and low tumor lysis rates in heavily pretreated mantle cell lymphoma.

Check out this October recap of OncLive’s coverage of the top news and expert insights in breast cancer.

Experts weigh genomic testing, treatment intensification, and radioligand sequencing in advanced prostate cancer care.

Exploratory BEHOLD-1 data show responses to mocertatug rezetecan in platinum-resistant ovarian cancer across B7-H4 expression levels.

The FDA has approved pimicotinib for patients with symptomatic tenosynovial giant cell tumors.

Frailty is common among older adults with blood cancers and strongly predicts survival, independent of age.

The PCR-based OncoMate MSI Dx Analysis System can now identify patients with MSI-H solid tumors who may be eligible for pembrolizumab.

The anti-CD19/CD20 CAR T-cell therapy will be studied in the phase 2 ABZT-121 trial after progression on commercial CAR T-cell therapy.

Updated BEHOLD-1 data show mocertatug rezetecan at its selected dose produced lasting responses in platinum-resistant ovarian cancer.

The decision removes the triple-class–refractory requirement and allows melflufen use after at least 2 prior lines of therapy.

Anktiva plus BCG improved efficacy vs BCG alone in cohort A of QUILT-2.005 in BCG-naive NMIBC.

The FDA set a June 25, 2027, target action date for gedatolisib plus fulvestrant in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer.

Read a refresh of hematologic cancer FDA news from October 2026, including the approval of a noncovalent BTK inhibitor in untreated CLL/SLL.

SER-155 showed early promise in reducing bloodstream infections in patients undergoing donor stem cell transplants for blood cancers.

Advances in endocrine therapy, immunotherapy, and ADCs frame unresolved breast cancer treatment questions ahead of BTG 2026.

During a recent OncLive Peer Exchange, multiple myeloma experts discussed how BCMA-directed therapies can be selected and sequenced.

Trine Jakobi Nøttrup, MD, PhD, discusses data for the hTERT-directed vaccine UV1 in BRCA wild-type recurrent ovarian cancer/



































































